Japan clinical trial of COVID-19 plasma therapy highlights slow-moving medical policy
Doctors are gearing up for clinical trials of convalescent plasma therapy, but many overseas hospitals have already moved on to other remedies.
Japan's Takeda seeks government approval for Moderna COVID-19 vaccine
While awaiting regulatory approval, Takeda plans to start distributing the Moderna vaccine in the first half of this year.
Moderna and Takeda to seek COVID-19 vaccine approval in Japan
The request, which could come as early as Friday, will be the third such application for regulatory approval.
Takeda starts clinical trial of Novavax COVID-19 vaccine in Japan
The drugmaker said it expects to gain results from a study on 200 Japanese participants age 20 or older in the second half of this year.
Takeda plans to supply 50 million doses of Moderna vaccine in Japan
Takeda Pharmaceutical Co. said Thursday it plans to supply 50 million doses of a coronavirus vaccine, developed by U.S. drugmaker Moderna Inc., in Japan from the first half of next year. The Japanese drugmaker said it will provide the vaccine based on a three-way agreement ...
Noncore operations sold by listed Japanese firms soar over ¥5 trillion
The number of businesses and operations sold by listed companies in January-September stood at 294, with the values of the deals totaling ¥5.1645 trillion.
Japan in vaccine talks with Moderna to cover 20 million people
If they reach a deal, it will be a major step toward the government's goal of securing enough medicine to inoculate everyone in the first half of 2021.
Takeda Pharmaceutical Co. agreed to sell its Japanese consumer health care business for ¥242 billion ($2.3 billion) to Blackstone Group Inc., which plans to take the over-the-counter medication unit public in about five years. For the drugmaker, the sale could represent one of the last ...
Takeda on track to sell OTC drug unit to Blackstone for ¥300 billion
Takeda is aiming to reduce debts after its purchase of Irish drugmaker Shire in January last year, the largest-ever Japanese acquisition of a foreign company.
Taisho emerges as lead bidder for Takeda $3 billion consumer unit
Taisho Pharmaceutical Holdings Co. has emerged as the leading contender to acquire Takeda Pharmaceutical Co.’s Japanese consumer health care business, according to people familiar with the matter. The company is in advanced talks with Takeda on terms of a transaction, and the two parties aim ...
Takeda considers sale of OTC drug unit to focus on profitable products
Takeda Pharmaceutical Co. is considering selling its over-the-counter medicine unit for around ¥400 billion ($3.7 billion) to focus on developing cancer treatments and other advanced medical-use drugs that can generate higher profitability, a source said Monday. The envisioned sale of Takeda Consumer Healthcare Co. comes ...
